NCT01526369
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior systemic therapy for metastatic disease (except one line of hormonal therapy for metastatic disease without Herceptin/trastuzumab); Patients with known central nervous system (CNS) metastasis
https://ClinicalTrials.gov/show/NCT01526369